Depression

Fathers in Sweden were less likely to receive new psychiatric diagnoses during their partner’s pregnancy and in the first months after birth, but diagnoses of depression and stress-related disorders rose by more than 30% toward the end of the child’s first year, according to a large national register study published in JAMA Network Open.

March 18, 2026 Ti AI ṣe iroyin

A new review of clinical trials suggests that psychedelics like psilocybin are effective for treating depression but offer no advantage over traditional antidepressants. Researchers accounted for the challenge of blinding in psychedelic studies, where participants can often tell if they received the drug. The findings indicate similar outcomes when compared to unblinded antidepressant trials.

Researchers at the University of Victoria have discovered that the protein Reelin could help repair leaky gut caused by chronic stress and alleviate depression symptoms. A single injection restored Reelin levels in preclinical models, showing antidepressant effects. The findings highlight the gut-brain connection in mental health.

January 21, 2026 Ti AI ṣe iroyin Ti ṣayẹwo fun ododo

An implanted device that stimulates the vagus nerve was associated with sustained improvements in symptoms, functioning and quality of life among adults with long-standing, treatment-resistant major depression, according to researchers reporting two-year follow-up data from the ongoing RECOVER study led by Washington University School of Medicine in St. Louis.

A study of more than 200,000 UK adults reports that chronic pain—especially when widespread—is associated with a greater risk of developing high blood pressure. The link appears to be partly mediated by depression and inflammation, underscoring the value of pain management and blood-pressure monitoring.

November 10, 2025 Ti AI ṣe iroyin

Neuroscientists from Columbia University and McGill University have discovered that high levels of the stress-related protein SGK1 are associated with depression and suicidal behavior in people who experienced childhood adversity. This finding suggests potential for new antidepressants targeting SGK1, particularly for those resistant to current treatments. The research highlights how early trauma alters brain chemistry differently from other forms of depression.